Protagenic Therapeutics (PTIX) — Strategic Asset Allocation Index
Protagenic Therapeutics (PTIX) has a Strategic Asset Allocation Index of 0.2% as of September 2018. Strategic assets (PP&E of $732.00 plus long-term investments of $0.00) total $732.00, measured against net assets of $323.03K. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Protagenic Therapeutics Strategic Asset Allocation Index (2016–2017)
This chart shows how Protagenic Therapeutics's Strategic Asset Allocation Index has evolved across 2 annual periods from 2016 to 2017. As of September 2018, the index stands at 0.2%, representing strategic assets of $732.00 against net assets of $323.03K USD. Explore Protagenic Therapeutics (PTIX) cash conversion ratio to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Protagenic Therapeutics (2016–2017)
The table below presents the year-by-year Strategic Asset Allocation Index for Protagenic Therapeutics from 2016 to 2017, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market cap of Protagenic Therapeutics.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2017 | 0.1% | $1.02K | $1.02K | $0.00 | $1.22 Million | ▲ +0.0 pp |
| 2016 | 0.0% | $1.10K | $1.10K | $0.00 | $2.48 Million | — |